Download Sample
Author
Prem Kumar with profound experience and sound knowledge across a wide range of market forecasting methods, demand f.....
Bevacizumab Market: By Application, By Distribution Channel, and Region Forecast 2020-2031
Bevacizumab Market: By Application, By Distribution Channel, and Region Forecast 2020-2031
Bevacizumab Market size was valued at US$ 9.3 billion in 2024 and is expected to reach US$ 17.2 billion by 2031, growing at a significant CAGR of 9.2% from 2025-2031. Bevacizumab, often known as Avastin, is a prescription drug used to treat a variety of tumours and specific eye problems. It is used for colon illness, cellular breakdown in the lungs, glioblastoma, and renal cell carcinoma and is given as a slow infusion into a vein (intravenous). Bevacizumab is used as a first-line treatment for several of these disorders. It is infused into the eye to treat age-related macular degeneration (intravitreal). When used to treat disease, bevacizumab has certain common side effects, including nosebleeds, migraines, hypertension, and dermatitis. Other serious side effects include gastrointestinal bleeding, mortality, negatively susceptible responses, blood clusters, and an increased risk of contamination. When used to treat eye disease, side effects can include vision problems and retinal separation.
Bevacizumab is a monoclonal neutralizer with anti-angiogenesis properties. It acts by slowing the growth of new blood vessels by inhibiting vascular endothelial development factor A (VEGF-A), a major VEGF antagonist. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Bevacizumab Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Bevacizumab Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
2025-2031Base Year
2024CAGR
9.2%Largest Market
North-AmericaFastest Growing Market
Europe
Bevacizumab is a drug that is used to treat a variety of disorders, including colorectal cancer, lung cancer, breast cancer, brain cancer, eye disease, kidney malignancies, cervical and ovarian cancer, and others. During the forecast period, the rising frequency of such diseases would be a major driver boosting the global market's growth. Aside from that, the rising prevalence of age-related macular degeneration is expected to aid market expansion in the future years.
North America accounted for larger revenue share in global bevacizumab market with significant CAGR and is expected to grow with highest CAGR during the forecast period owing to presence of large number of prominent players and availability of reimbursement policies, rising adoption of new technologies and increasing healthcare awareness among the people about the early diagnosis. Europe and Asia Pacific market projected to grow at significant rate over the forecasted period owing to increasing aging population and presence of rapidly developing countries like India and China coupled with improvement in government funding dominates the bevacizumab market over the forecasted period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 9.3 billion |
|
Market Size in 2031 |
US$ 17.2 billion |
|
Market CAGR |
9.2% |
|
By Application |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Bevacizumab market size was valued at US$ 9.3 billion in 2024 and is expected to reach US$ 17.2 billion by 2031, growing at a significant CAGR of 9.2%.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.Global Bevacizumab Market Introduction |
| 2.1.Global Bevacizumab Market - Taxonomy |
| 2.2.Global Bevacizumab Market - Definitions |
| 2.2.1.Application |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Bevacizumab Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Bevacizumab Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Bevacizumab Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Colorectal Cancer |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Lung Cancer |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Breast Cancer |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Renal Cancer |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Brain Cancer |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Eye Diseases |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Bevacizumab Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Hospital Pharmacy |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacy |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacy |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Bevacizumab Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Bevacizumab Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Colorectal Cancer |
| 8.1.2.Lung Cancer |
| 8.1.3.Breast Cancer |
| 8.1.4.Renal Cancer |
| 8.1.5.Brain Cancer |
| 8.1.6.Eye Diseases |
| 8.1.7.Others |
| 8.2. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacy |
| 8.2.2.Retail Pharmacy |
| 8.2.3.Online Pharmacy |
| 8.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Bevacizumab Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Colorectal Cancer |
| 9.1.2.Lung Cancer |
| 9.1.3.Breast Cancer |
| 9.1.4.Renal Cancer |
| 9.1.5.Brain Cancer |
| 9.1.6.Eye Diseases |
| 9.1.7.Others |
| 9.2. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacy |
| 9.2.2.Retail Pharmacy |
| 9.2.3.Online Pharmacy |
| 9.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Bevacizumab Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Colorectal Cancer |
| 10.1.2.Lung Cancer |
| 10.1.3.Breast Cancer |
| 10.1.4.Renal Cancer |
| 10.1.5.Brain Cancer |
| 10.1.6.Eye Diseases |
| 10.1.7.Others |
| 10.2. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacy |
| 10.2.2.Retail Pharmacy |
| 10.2.3.Online Pharmacy |
| 10.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Bevacizumab Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Colorectal Cancer |
| 11.1.2.Lung Cancer |
| 11.1.3.Breast Cancer |
| 11.1.4.Renal Cancer |
| 11.1.5.Brain Cancer |
| 11.1.6.Eye Diseases |
| 11.1.7.Others |
| 11.2. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacy |
| 11.2.2.Retail Pharmacy |
| 11.2.3.Online Pharmacy |
| 11.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Bevacizumab Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Colorectal Cancer |
| 12.1.2.Lung Cancer |
| 12.1.3.Breast Cancer |
| 12.1.4.Renal Cancer |
| 12.1.5.Brain Cancer |
| 12.1.6.Eye Diseases |
| 12.1.7.Others |
| 12.2. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacy |
| 12.2.2.Retail Pharmacy |
| 12.2.3.Online Pharmacy |
| 12.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Allurion Technologies (U.S.) |
| 13.2.2.Silimed inc. (Brazil) |
| 13.2.3.Obalon Therapeutics Inc. (U.S.) |
| 13.2.4.Districlass Medical (S.A.) (France) |
| 13.2.5.ReShape Medical Inc. (U.S.) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Prem Kumar with profound experience and sound knowledge across a wide range of market forecasting methods, demand forecasting, and pricing analysis, I am able to make precise projections. I have extensive practical knowledge in Time Series Analysis (TSA), Simple Linear Regression (SLR), Multiple Linear Regression (MLR), Seasonality & Trend Forecasting, and Forecasting Models for New Products, among others. Additionally, I have hands-on experience with tools such as Power BI and SQL. I am highly committed, self-motivated, and possess a strong entrepreneurial spirit. Over the past 8 years, my team and I have built a robust clientele in various sectors, including Packaging, Pharma, Medical Devices, Oil & Gas, and Chemicals & Materials. We have provided a wide range of services, from management consulting to market forecasting and survey-related projects. I am particularly proud to have provided consulting services to one of the industry’s leading COVID-19 vaccine manufacturers for a packaging-related project. In the packaging space, I have served clients across a range of segments, including packaging printing, consumer packaging, flexible packaging, rigid packaging, and pharmaceutical packaging, to name a few. I deeply appreciate the efforts of my team and am grateful to our clients for their continued trust.